In sum, these results suggest that the KDM3A-KLF2-IRF4 pathway critically contributes to MM cell survival and homing to the bone marrow, making this axis a potentially valuable therapeutic target for MM. This evidence concerns the gene IRF4 and Miyoshi myopathy.